Dai ichi Life Insurance Company Ltd Decreases Position in Illumina, Inc. (NASDAQ:ILMN)

Dai ichi Life Insurance Company Ltd trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,131 shares of the life sciences company’s stock after selling 435 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Illumina were worth $539,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Empowered Funds LLC lifted its stake in shares of Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares during the last quarter. Caprock Group LLC increased its stake in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares during the period. UMB Bank n.a. lifted its position in Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after purchasing an additional 88 shares during the last quarter. Integrated Advisors Network LLC boosted its stake in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after purchasing an additional 90 shares during the period. Finally, Moors & Cabot Inc. grew its holdings in shares of Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after purchasing an additional 95 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ILMN. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Wednesday, August 28th. StockNews.com assumed coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating for the company. JPMorgan Chase & Co. lifted their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, UBS Group upped their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Trading Up 1.0 %

Illumina stock opened at $144.36 on Friday. Illumina, Inc. has a one year low of $93.51 and a one year high of $156.66. The business’s fifty day moving average is $141.62 and its 200 day moving average is $125.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock has a market capitalization of $22.90 billion, a PE ratio of -14.49 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the firm earned $0.33 earnings per share. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, sell-side analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.